Farrer Park Hospital Underscores Commitment to Sustainability with Ongoing Green Initiatives
SINGAPORE, July 6, 2022 /PRNewswire/ -- Sustainability efforts were already embedded in Farrer Park Hospital's ("FPH" or "the Hospital") DNA since its early phase of conceptualisation. Since FPH went operational in 2014, the Hospital has attained optimal energy savings of 30 per cent annually. Within the Hospital, light fittings with motion sensors that are...
Fosun receives S&P report: Fosun has flexibility to replenish cash and has adequate resources to manage debt maturities
HONG KONG, July 6, 2022 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International") said S&P Global Rating has published a report on 23 June, stating that Fosun has adequate resources to meet its upcoming debt maturities over the next six to 12 months. According to Fosun International's 2021 annual report, Fosun International has a sound and...
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in...
Deep Longevity Announces Important Operational Update
HONG KONG, July 6, 2022 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a Hong Kong-based AI innovator and a leading provider of deep biomarkers of aging and longevity is pleased to announce several important updates which contribute to its growing journey. Hiring...
harrison.ai and Sonic Healthcare join forces to launch ‘franklin.ai’, bringing Artificial Intelligence (AI) to pathology
franklin.ai aims to apply the latest methodologies in artificial intelligence (AI) to put groundbreaking AI tools into the hands of pathologists. SYDNEY, July 6, 2022 /PRNewswire/ -- harrison.ai, the clinically led healthcare AI platform and Sonic Healthcare (ASX:SHL), the global medical diagnostics leader, have this week officially launched 'franklin.ai', a joint venture to advance patient care by integrating digital pathology...
Esco Lifesciences Group Strengthens IVF Portfolio by Acquiring Evidence Solution
SINGAPORE, July 6, 2022 /PRNewswire/ -- Esco Lifesciences Group ("Esco", the "Company") announces the full acquisition of Evidence Solution ("Evidence"), a Danish software company offering In Vitro Fertilization (IVF) management technologies and quality management systems ("Evidence witness system"). Evidence witness system is a witnessing, labelling, workflow scheduling and traceability system, specifically built...
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and better position its oral drug pipeline of COVID-19 HANGZHOU, China and SHAOXING, China, July...
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022
Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 6, 2022 /PRNewswire/ -- Global Cord...
Eurofins Discovery Announces Acquisition of DiscoveryBioMed
SAN DIEGO, July 6, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the acquisition of DiscoveryBioMed, a contract research organization (CRO) focused on developing novel human bioassays utilizing cells from diseased and normal human...
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved...
